Browse: Departments Dates Agencies
SUBJECT CATEGORY: New Animal Drugs for Use in Animal Feeds; Halofuginone and Roxarsone
DOCUMENT SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Alpharma, Inc. The NADA provides for use of approved, singleingredient halofuginone hydrobromide and roxarsone Type A medicated articles to make twoway combination Type C medicated feeds used for prevention of coccidiosis, increased rate of weight gain, improved feed efficiency, and improved pigmentation in broiler and replacement chickens.
SUMMARY: Halofuginone and roxarsone,
Also, Sec. 558.530 is editorially amended in paragraphs (a) and (d)(5) to simplify the regulation.
In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
The agency has determined under 21 CFR 25.33(a)(2) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801808.
[[Page 45712]]
List of Subjects in 21 CFR Part 558
Animal drugs, Animal feeds.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:
1. The authority citation for 21 CFR part 558 continues to read as follows:
Authority: 21 U.S.C. 360b, 371.
2. Section 558.265 is amended by adding paragraphs (c)(1)(viii) and (c)(3)(ii) to read as follows:
Sec. 558.265 Halofuginone hydrobromide.
* * * * *
(c) * * *
(1) * * *
(viii) Amount per ton. Halofuginone hydrobromide, 2.72 grams plus roxarsone, 22.7 to 45.4 grams.
(A) Indications for use. For the prevention of coccidiosis caused
by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati,
and E. maxima; for increased rate of weight gain, improved feed efficiency, and improved pigmentation.
(B) Limitations. Feed continuously as sole ration to replacement
cage laying chickens until 20 weeks of age. Feed continuously as sole
ration to replacement broiler breeder chickens until 16 weeks of age.
Use as the sole source of organic arsenic; drug overdose or lack of
water intake may result in leg weakness or paralysis. Do not feed to
laying chickens or waterfowl. Withdraw 5 days before slaughter. * * * * *
(3) * * *
(ii) Amount per ton. Halofuginone hydrobromide, 2.72 grams plus roxarsone, 22.7 to 45.4 grams.
(A) Indications for use. For the prevention of coccidiosis caused
by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati,
and E. maxima; for increased rate of weight gain, improved feed efficiency, and improved pigmentation.
(B) Limitations. Feed continuously as sole ration to replacement
cage laying chickens until 20 weeks of age. Feed continuously as sole
ration to replacement broiler breeder chickens until 16 weeks of age.
Use as the sole source of organic arsenic; drug overdose or lack of
water intake may result in leg weakness or paralysis. Do not feed to
laying chickens or waterfowl. Withdraw 5 days before slaughter.
3. Section 558.530 is amended by revising paragraphs (a) and (d)(5) and by removing paragraph (d)(6) to read as follows:
Sec. 558.530 Roxarsone.
(a) Approvals. Type A medicated articles: 10, 20, 50, and 80
percent to 046573 in Sec. 510.600(c) of this chapter for use as in paragraphs (d)(1) through (d)(4) of this section.
* * * * *
(d) * * *
(5) Permitted combinations. It may be used in accordance with this section in combination with:
(i) Aklomide as in Sec. 558.35.
(ii) Amprolium as in Sec. 558.55.
(iii) Amprolium and ethopabate as in Sec. 558.58.
(iv) Bacitracin methylene disalicylate as in Sec. 558.76. (v) Bacitracin zinc as in Sec. 558.78.
(vi) Bambermycins and bambermycins plus certain anticoccidials as in Sec. 558.95.
(vii) Chlortetracycline as in Sec. 558.128.
(viii) Clopidol as in Sec. 558.175.
(ix) Decoquinate alone or in combination as in Sec. 558.195. (x) [Reserved]
(xi) Halofuginone alone or in combination as in Sec. 558.265.
(xii) Lasalocid alone or in combination as in Sec. 558.311.
(xiii) Monensin alone or in combination as in Sec. 558.355.
(xiv) Narasin alone or in combination as in Sec. 558.363. (xv) Nequinate as in Sec. 558.365.
(xvi) Nicarbazin alone or in combination as in Sec. 558.366. (xvii) Nitromide and sulfanitran as in Sec. 558.376.
(xviii) Penicillin and zoalene as in Sec. 558.680.
(xix) Robenidine hydrochloride as in Sec. 558.515.
(xx) Salinomycin alone or in combination as in Sec. 558.550.
(xxi) Semduramicin alone or in combination as in Sec. 558.555.
(xxii) Sulfadimethoxine, ormetoprim as in Sec. 558.575.
(xxiii) Zoalene alone or in combination as in Sec. 558.680.
Dated: July 17, 2000.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 0018744 Filed 72400; 8:45 am]
BILLING CODE 416001F
FOR FURTHER INFORMATION CONTACT Charles J. Andres, Center for Veterinary Medicine (HFV128), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 3018271600.
14 CFR Part 39 40 CFR Part 52 14 CFR Part 71 33 CFR Part 165 50 CFR Part 679 47 CFR Part 73 26 CFR Part 1 40 CFR Part 180 33 CFR Part 117 50 CFR Part 17 44 CFR Part 67 50 CFR Part 648 14 CFR Part 97 33 CFR Part 100 40 CFR Part 63 50 CFR Part 622 44 CFR Part 65 50 CFR Part 660 26 CFR Part 301 39 CFR Part 111 40 CFR Part 300 6 CFR Part 5 40 CFR Part 271 47 CFR Part 64 40 CFR Parts 52 and 81 50 CFR Part 665 44 CFR Part 64 10 CFR Part 50 49 CFR Part 571 47 CFR Part 76